OBJECTIVE: Reduced early insulin response has been shown to predict type 1 diabetes (T1D) in first-degree relatives of diabetic patients, while its role, as well as that of insulin resistance, has remained poorly defined in young children representing the general population. The predictive values of these markers and their relation to other risk factors of T1D were assessed in children with advanced β-cell autoimmunity, i.e. persistent positivity for two or more autoantibodies. DESIGN AND METHODS: Intravenous glucose tolerance tests (IVGTTs) were carried out in 218 children with HLA-DQB1-conferred disease susceptibility and advanced β-cell autoimmunity. Baseline, metabolic and growth data were compared between children progressing to diabetes and those remaining unaffected. Hazard ratios for the disease predictors and the progression rate of T1D were assessed. RESULTS: Children developing T1D were younger at seroconversion, progressed more rapidly to advanced β-cell autoimmunity and had lower first-phase insulin response (FPIR) and homeostasis model assessment index for insulin resistance (HOMA-IR) than those remaining non-diabetic. The levels of HOMA-IR/FPIR, islet cell antibodies, insulin autoantibodies (IAA) and islet antigen 2 antibodies (IA-2A) were higher in progressors. BMI SDS, FPIR, age at IVGTT and levels of IAA and IA-2A were predictive markers for T1D. CONCLUSIONS: Young age, higher BMI SDS, reduced FPIR and higher levels of IAA and IA-2A predicted T1D in young children with HLA-DQB1-conferred disease susceptibility and advanced β-cell autoimmunity. Disease risk estimates were successfully stratified by the assessment of metabolic status and BMI. The role of insulin resistance as an accelerator of the disease process was minor.
OBJECTIVE: Reduced early insulin response has been shown to predict type 1 diabetes (T1D) in first-degree relatives of diabeticpatients, while its role, as well as that of insulin resistance, has remained poorly defined in young children representing the general population. The predictive values of these markers and their relation to other risk factors of T1D were assessed in children with advanced β-cell autoimmunity, i.e. persistent positivity for two or more autoantibodies. DESIGN AND METHODS: Intravenous glucose tolerance tests (IVGTTs) were carried out in 218 children with HLA-DQB1-conferred disease susceptibility and advanced β-cell autoimmunity. Baseline, metabolic and growth data were compared between children progressing to diabetes and those remaining unaffected. Hazard ratios for the disease predictors and the progression rate of T1D were assessed. RESULTS:Children developing T1D were younger at seroconversion, progressed more rapidly to advanced β-cell autoimmunity and had lower first-phase insulin response (FPIR) and homeostasis model assessment index for insulin resistance (HOMA-IR) than those remaining non-diabetic. The levels of HOMA-IR/FPIR, islet cell antibodies, insulin autoantibodies (IAA) and islet antigen 2 antibodies (IA-2A) were higher in progressors. BMI SDS, FPIR, age at IVGTT and levels of IAA and IA-2A were predictive markers for T1D. CONCLUSIONS: Young age, higher BMI SDS, reduced FPIR and higher levels of IAA and IA-2A predicted T1D in young children with HLA-DQB1-conferred disease susceptibility and advanced β-cell autoimmunity. Disease risk estimates were successfully stratified by the assessment of metabolic status and BMI. The role of insulin resistance as an accelerator of the disease process was minor.
Authors: Annelien Van Dalem; Simke Demeester; Eric V Balti; Katelijn Decochez; Ilse Weets; Evy Vandemeulebroucke; Ursule Van de Velde; An Walgraeve; Nicole Seret; Christophe De Block; Johannes Ruige; Pieter Gillard; Bart Keymeulen; Daniel G Pipeleers; Frans K Gorus Journal: Diabetologia Date: 2015-09-26 Impact factor: 10.122
Authors: Emily K Sims; Brian N Bundy; Kenneth Stier; Elisavet Serti; Noha Lim; S Alice Long; Susan M Geyer; Antoinette Moran; Carla J Greenbaum; Carmella Evans-Molina; Kevan C Herold Journal: Sci Transl Med Date: 2021-03-03 Impact factor: 17.956
Authors: Maarit K Koskinen; Olli Helminen; Jaakko Matomäki; Susanna Aspholm; Juha Mykkänen; Marjaana Mäkinen; Ville Simell; Mari Vähä-Mäkilä; Tuula Simell; Jorma Ilonen; Mikael Knip; Riitta Veijola; Jorma Toppari; Olli Simell Journal: Eur J Endocrinol Date: 2015-11-30 Impact factor: 6.664
Authors: Annelien Van Dalem; Simke Demeester; Eric V Balti; Bart Keymeulen; Pieter Gillard; Bruno Lapauw; Christophe De Block; Pascale Abrams; Eric Weber; Ilse Vermeulen; Pieter De Pauw; Daniël Pipeleers; Ilse Weets; Frans K Gorus Journal: PLoS One Date: 2016-12-01 Impact factor: 3.240
Authors: Michael G Voss; David D Cuthbertson; Mario M Cleves; Ping Xu; Carmella Evans-Molina; Jerry P Palmer; Maria J Redondo; Andrea K Steck; Markus Lundgren; Helena Larsson; Wayne V Moore; Mark A Atkinson; Jay M Sosenko; Heba M Ismail Journal: Diabetes Care Date: 2021-08-06 Impact factor: 17.152